Four patients developed clinically important portal hypertension with histological features of idiopathic portal hypertension while they were receiving cytotoxic drugs for chronic myeloid leukaemia and Hodgkin's disease. Mild sclerosis of some small portal triads was the only abnormality seen at light microscopical examination in three of the four cases. In the remaining case light microscopical findings seemed to be normal. Two cases examined by electron microscopy showed perisinusoidal fibrosis; in one case this was the only abnormality detected.
Idiopathic portal hypertension in the absence of cirrhosis or other demonstrable causes of portal hypertension is uncommon, accounting for 3-40h of all cases in Western countries' but 25-30% in India2 and Japan.3 Fibrosis of small portal triads may be present and in most the aetiology is unknown: some have been associated with exposure to arsenic,4 5 vinyl chloride,56 and vitamin A.7 Only rarely have chemotherapeutic agents been implicated. 8 Key et al recently attributed non-cirrhotic portal hypertension to nodular regenerative hyperplasia (NRH) in four patients with chronic myeloid leukaemia who were treated with busulphan and thioguanine.9 NRH is rare and may be difficult to diagnose on small needle biopsy specimens.'0 In reported series of patients with NRH" 12 mild fibrosis of small portal tracts was noted in most, and it has been suggested that the regenerative nodules may develop as a response to obliterative portal venopathy. " We report the development of portal hypertension in four patients after treatment of chronic myeloid leukaemia and Hodgkin's disease with chemotherapeutic drugs. Mild A 55 year old man developed chronic myeloid leukaemia in March 1983. The Philadelphia chromosome, however, was not present. The spleen was palpable 4 cm below the costal margin, but the liver was not enlarged and liver function tests were normal. He was entered into the MRC CML II trial and received busulphan (total dose 252 mg) and thioguanine (10-1 g) with good control of his disease. Serial liver function tests are shown in figure 1 . In December 1983 he developed haemoatemesis and malaena due to a bleeding gastric ulcer, seen on endoscopic examination. Chemotherapy was stopped and cimetidine started. Repeat endoscopy in March 1984 was normal. In September 1984, due to increasing leucocyte counts, busulphan and thioguanine were restarted. In December 1984 21 months after starting treatment haematemesis recurred and another endoscopy showed bleeding oesophageal varices; these were treated with sclerotherapy. Chemotherapy was continued until September 1985 when recurrent variceal haemorrhage uncontrolled by sclerotherapy required laparotomy and removal of the spleen. Portal venography showed increased pressure in the portal vein but no other abnormality. In particular, there was no evidence ofobstruction of the portal tract. Chemotherapy was changed to hydroxyurea and since then he has had no further problems. CASE 3 A 34 year old woman presented in 1981 with cervical lymphadenopathy. Biopsy and staging showed nodular sclerosing Hodgkin's disease (stage IIA). She was treated with radiotherapy with regression of the disease. In March 1985 she developed recurrent Hodgkin's disease in the lungs. Liver function tests and a barium swallow at this time were normal. She was treated with combination chemotherapy using chlorambucil, vinblastine, procarbazine and prednisolone (ClVPP) for six courses with regression of her pulmonary disease. Shortly afterwards she developed pronounced abnormalities of liver function tests, particularly alkaline phosphatase (figure 1). Her liver was not enlarged and an open liver biopsy specimen was obtained. Because of the severely increased alkaline phosphatase activity an endoscopic retrograde cholangiopancreatogram was performed to assess the biliary tree and pancreas. Mild deformity of the intrahepatic ducts in the left lobe of the liver was seen but no other abnormality. Spider naevi were noted and a barium swallow in February 1988 showed oesophageal varices. CASE 4 Chronic myeloid leukaemia was diagnosed in a 68 year old woman in December 1986..She was entered into the MRC CML II trial and received busulphan (total dose 550 mg) and thioguanine (total dose 23 6 g) until May 1988 when thioguanine was stopped because of concern about potential hepatotoxicity associated with its use. At diagnosis slightly increased transaminase activities were present (< 2 x N) which persisted along with a mild increase in alkaline phosphatase during treatment. Busul- At necropsy a portal venogram showed delayed filling with "cut off' of small portal vein radicles but not evidence of thrombosis ( figure  2 ). This appearance was not seen when control liver tissue was studied. Histological examination of the liver before death and at necropsy had shown normal lobular architecture ( figure  3 ). The sinusoids were infiltrated by leukaemic cells and there was fibrosis of small portal triads with narrowing of portal venules (figure 4). Electron microscopic examination showed fibrosis in the perisinusoidal space of Disse (figure 5).
Figure 4 Photomicrograph ofportal triad containing bile ducts and hepatic artery but no distinguishable portal vein. There is an increase in portalfibrosis (Orcein Shikata).
CASE 2
The liver biopsy specimen at laparotomy showed normal architecture with no evidence of leukaemic infiltration of sinusoids. There was mild sclerosis of small portal triads similar to that seen in figure 4. CASE 3 A liver biopsy specimen seemed to be normal on light microscopical examination. Electron microscopic examination showed perisinusoidal fibrosis in the space of Disse, similar to that seen in figure 5 . CASE cases serial biopsy specimens showed progression to hepatoportal sclerosis, suggesting that this may be a subsequent manifestation of fibroblastic proliferation.
Key et al have recently described five patients with chronic myeloid leukaemia, treated with busulphan and thioguanine, who developed portal hypertension with oesophageal varices.9 Histological findings for four showed small intrahepatic nodules, interpreted as nodular regenerative hyperplasia, a rare cause of portal hypertension. This is a difficult diagnosis to make because of the limited material available: indeed it may be impossible to establish without a wedge biopsy.'0 Evaluation of series of patients with nodular regenerative hyperplasia has shown mild fibrosis affecting the portal tracts in most,"1 12 and it has been postulated that the hyperplastic nodules arise as a secondary response to obliterative portal venopathy." There may therefore be an association between this disorder and other conditions associated with fibrosis of portal tracts.
In the Medical Research Council's second therapeutic trial in chronic myeloid leukaemia (MRC CML II trial) in which single agent treatment (busulphan) was compared with combination treatment (busulphan and thioguanine) 18 tion associated with the use of these agents, and will be required to determine more clearly the incidence and pathogenesis of this disorder.
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